Chiodi F, Biberfeld G, Parks E, Norrby E, Mufson M
Department of Virology, Karolinska Institute, School of Medicine, Stockholm, Sweden.
Eur J Epidemiol. 1989 Mar;5(1):42-6. doi: 10.1007/BF00145043.
Antibodies to Human Immunodeficiency Virus type 1 (HIV-1) and type 2 (HIV-2) were investigated, using site-directed enzyme immunoassay (ELISA), in 320 specimens obtained from three remote, African tribes during 1969-1971. Using HIV-1 E34/E32 ELISA and HIV-2 149 ELISA, assay were conducted on 101 serum specimens from the Korekore tribe of Zimbabwe, 93 specimens from the Mano tribe of Liberia, and 126 specimens from the Turkana tribe of Kenya; specimens which tested positive in ELISA were further tested by radioimmunoprecipitation assay (RIPA) and Western blot (WB). Two serum specimens from the Mano tribe of Liberia gave OD 492 nm values greater than 0.2 in HIV E34/E32 ELISA in all three runs. These two specimens reacted with HIV-1 envelope proteins gp160 and gp120 and the internal protein p24 in RIPA and WB; however, the reactivity was uncostant. All other serum specimens were negative for HIV-1 and HIV-2 antibodies. Site directed ELISA serology for HIV-1 and HIV-2 gave very low rates of false positive reactivity. Thus, reaction with HIV-1 antigen was identified in two persons of one tribe in Liberia in 1971, but HIV-2 antibodies were not detected in this tribe; HIV-1 and HIV-2 antibodies were absent during the late 1960's and early 1970's from two African tribes resident in Zimbabwe and Kenya.
1969年至1971年期间,利用定点酶免疫分析法(ELISA)对从三个偏远非洲部落采集的320份样本进行了1型人类免疫缺陷病毒(HIV-1)和2型人类免疫缺陷病毒(HIV-2)抗体检测。使用HIV-1 E34/E32 ELISA和HIV-2 149 ELISA对来自津巴布韦科雷科雷部落的101份血清样本、来自利比里亚马诺部落的93份样本以及来自肯尼亚图尔卡纳部落的126份样本进行了检测;ELISA检测呈阳性的样本进一步通过放射免疫沉淀试验(RIPA)和蛋白质印迹法(WB)进行检测。利比里亚马诺部落的两份血清样本在所有三次HIV E34/E32 ELISA检测中,492 nm波长处的光密度(OD)值均大于0.2。这两份样本在RIPA和WB检测中与HIV-1包膜蛋白gp160和gp120以及内部蛋白p24发生反应;然而,反应并不稳定。所有其他血清样本的HIV-1和HIV-2抗体均为阴性。针对HIV-1和HIV-2的定点ELISA血清学检测假阳性反应率非常低。因此,1971年在利比里亚的一个部落中,有两人被检测出与HIV-1抗原发生反应,但该部落未检测到HIV-2抗体;20世纪60年代末至70年代初,居住在津巴布韦和肯尼亚的两个非洲部落均未检测到HIV-1和HIV-2抗体。